MSF - Vital Signs

Sign in Subscribe

MSF

A collection of 2 posts

Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations

Inside EU Health

Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations

EMA recommends five new medicines for approval; MSF denied access to Gilead HIV-prevention drug; Europe invests €244 million to fast-track next-generation treatments for deadly infections; WHO members extend negotiations on pathogen sharing framework

MSF denied access to Gilead HIV-prevention drug

Access to Medicine

MSF denied access to Gilead HIV-prevention drug

Médecins Sans Frontières accuses Gilead Sciences of blocking access to its HIV-prevention drug lenacapavir.